Lyell Immunopharma Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial

Reuters12-08 05:30

<a href="https://laohu8.com/S/LYEL">Lyell Immunopharma</a> Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial

Lyell Immunopharma Inc. has announced new clinical and translational data from its ongoing trial of rondecabtagene autoleucel (ronde-cel, LYL314) in patients with large B-cell lymphoma. The results were presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. As of the September 5, 2025, data cutoff, ronde-cel demonstrated a 93% overall response rate and a 76% complete response rate in the third- or later-line setting, with a median progression-free survival of 18 months. In the second-line setting, patients achieved an 83% overall response rate and a 61% complete response rate. The safety profile was reported as manageable, with no high-grade cytokine release syndrome and 5% or fewer patients experiencing Grade 3 or higher ICANS following dexamethasone prophylaxis. Presentation materials and a webcast replay will be available on the Lyell website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598165-en) on December 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589806988?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589806988","market":"nz","top_or_hot":-1,"title":"Lyell Immunopharma Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LYEL\">Lyell Immunopharma</a> Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lyell Immunopharma Inc. has announced new clinical and translational data from its ongoing trial of rondecabtagene autoleucel (ronde-cel, LYL314) in patients with large B-cell lymphoma. The results were presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition. As of the September 5, 2025, data cutoff, ronde-cel demonstrated a 93% overall response rate and a 76% complete response rate in the third- or later-line setting, with a median progression-free survival of 18 months. In the second-line setting, patients achieved an 83% overall response rate and a 61% complete response rate. The safety profile was reported as manageable, with no high-grade cytokine release syndrome and 5% or fewer patients experiencing Grade 3 or higher ICANS following dexamethasone prophylaxis. Presentation materials and a webcast replay will be available on the Lyell website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598165-en) on December 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lyell Immunopharma Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLyell Immunopharma Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LYEL\">Lyell Immunopharma</a> Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lyell Immunopharma Inc. has announced new clinical and translational data from its ongoing trial of rondecabtagene autoleucel (ronde-cel, LYL314) in patients with large B-cell lymphoma. The results were presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition. As of the September 5, 2025, data cutoff, ronde-cel demonstrated a 93% overall response rate and a 76% complete response rate in the third- or later-line setting, with a median progression-free survival of 18 months. In the second-line setting, patients achieved an 83% overall response rate and a 61% complete response rate. The safety profile was reported as manageable, with no high-grade cytokine release syndrome and 5% or fewer patients experiencing Grade 3 or higher ICANS following dexamethasone prophylaxis. Presentation materials and a webcast replay will be available on the Lyell website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598165-en) on December 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL98NtBk:1","article_id":"2589806988","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589806988","pubTimestamp":1765143014,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lyell Immunopharma Inc. has announced new clinical and translational data from its ongoing trial of rondecabtagene autoleucel  in patients with large B-cell lymphoma. The results were presented at the 67th American Society of Hematology  Annual Meeting and Exposition. As of the September 5, 2025, data cutoff, ronde-cel demonstrated a 93% overall response rate and a 76% complete response rate in the third- or later-line setting, with a median progression-free survival of 18 months. In the second-line setting, patients achieved an 83% overall response rate and a 61% complete response rate. The safety profile was reported as manageable, with no high-grade cytokine release syndrome and 5% or fewer patients experiencing Grade 3 or higher ICANS following dexamethasone prophylaxis. Presentation materials and a webcast replay will be available on the Lyell website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4505":"高瓴资本持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4588":"碎股","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4539":"次新股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LYEL":"Lyell Immunopharma, Inc."},"translate_title":"Lyell Immunopharma报告Ronde-Cel在大B细胞淋巴瘤试验中的高缓解率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LYEL":0.9,"NDAQ":0.9},"content_text":"Lyell Immunopharma Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial\n    \n\n        Lyell Immunopharma Inc. has announced new clinical and translational data from its ongoing trial of rondecabtagene autoleucel (ronde-cel, LYL314) in patients with large B-cell lymphoma. The results were presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. As of the September 5, 2025, data cutoff, ronde-cel demonstrated a 93% overall response rate and a 76% complete response rate in the third- or later-line setting, with a median progression-free survival of 18 months. In the second-line setting, patients achieved an 83% overall response rate and a 61% complete response rate. The safety profile was reported as manageable, with no high-grade cytokine release syndrome and 5% or fewer patients experiencing Grade 3 or higher ICANS following dexamethasone prophylaxis. Presentation materials and a webcast replay will be available on the Lyell website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598165-en) on December 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589806988","isCrawlerRequest":true}